Nuvectra Corp (NASDAQ:NVTR) Given Consensus Recommendation of “Hold” by Brokerages

Share on StockTwits

Nuvectra Corp (NASDAQ:NVTR) has been given an average recommendation of “Hold” by the six ratings firms that are currently covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $7.00.

Several brokerages have recently commented on NVTR. ValuEngine lowered Nuvectra from a “hold” rating to a “sell” rating in a research note on Thursday, November 14th. Raymond James lowered Nuvectra from an “outperform” rating to a “market perform” rating in a research note on Wednesday, November 13th. Finally, Zacks Investment Research lowered Nuvectra from a “buy” rating to a “hold” rating in a research note on Wednesday, October 23rd.

Several institutional investors have recently made changes to their positions in the company. Valeo Financial Advisors LLC acquired a new position in Nuvectra during the 3rd quarter worth about $30,000. Tower Research Capital LLC TRC lifted its stake in Nuvectra by 1,431.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 13,030 shares of the company’s stock worth $44,000 after acquiring an additional 12,179 shares in the last quarter. Edge Wealth Management LLC lifted its stake in Nuvectra by 24.9% during the 3rd quarter. Edge Wealth Management LLC now owns 50,140 shares of the company’s stock worth $68,000 after acquiring an additional 10,000 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Nuvectra by 304.3% during the 2nd quarter. JPMorgan Chase & Co. now owns 33,857 shares of the company’s stock worth $110,000 after acquiring an additional 25,482 shares in the last quarter. Finally, Gamco Investors INC. ET AL lifted its stake in Nuvectra by 34.7% during the 3rd quarter. Gamco Investors INC. ET AL now owns 105,194 shares of the company’s stock worth $143,000 after acquiring an additional 27,100 shares in the last quarter. 75.17% of the stock is currently owned by institutional investors and hedge funds.

Shares of NASDAQ:NVTR opened at $0.13 on Wednesday. Nuvectra has a 52-week low of $0.13 and a 52-week high of $20.85. The business has a fifty day moving average of $0.13 and a two-hundred day moving average of $1.10. The stock has a market cap of $2.33 million, a P/E ratio of -0.04 and a beta of 0.69. The company has a quick ratio of 4.42, a current ratio of 4.86 and a debt-to-equity ratio of 0.58.

About Nuvectra

Nuvectra Corporation, a neurostimulation medical device company, develops and commercializes neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets. The company offers Algovita, a spinal cord stimulation system for the treatment of chronic intractable pain of the trunk and limbs.

Read More: Asset Allocation

Receive News & Ratings for Nuvectra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

HBT Financial  Given Average Rating of “Buy” by Analysts
HBT Financial Given Average Rating of “Buy” by Analysts
Drexel Morgan & Co. Has $1.63 Million Stock Holdings in Caterpillar Inc.
Drexel Morgan & Co. Has $1.63 Million Stock Holdings in Caterpillar Inc.
Medtronic PLC  Shares Sold by Drexel Morgan & Co.
Medtronic PLC Shares Sold by Drexel Morgan & Co.
Drexel Morgan & Co. Reduces Stock Holdings in Walt Disney Co
Drexel Morgan & Co. Reduces Stock Holdings in Walt Disney Co
Drexel Morgan & Co. Reduces Holdings in Deere & Company
Drexel Morgan & Co. Reduces Holdings in Deere & Company
Analysts Anticipate China Yuchai International Limited  to Post $0.32 Earnings Per Share
Analysts Anticipate China Yuchai International Limited to Post $0.32 Earnings Per Share


© 2006-2020 Ticker Report